Missed appointments in Ethiopia are a clinical failure, not an empty chair

Clinic software vendors usually frame missed appointments as a revenue problem: an empty slot is money that did not arrive. In Ethiopian chronic-disease care, the published evidence frames it differently — a missed appointment is a patient who stopped being treated, and the studies measure it as such.

Hypertension: two in five miss follow-up

A cross-sectional study of 401 hypertensive patients across four South Gondar hospitals (data collected January–February 2023, 95% response rate) found 39.2% were non-adherent to their appointment follow-up 1.

The associated factors are the useful part, because they are all recognisable at the front desk 1:

Adjusted odds ratios with 95% confidence intervals; 1.0 means no association. Every one of these is visible in the chart before the patient fails to arrive.

Source: Yirga et al. 2024, four South Gondar hospitals, n=401 [1]

Show data table

	Estimate	95% CI
Absence of perceived symptoms	4.98	2.89–8.59
Pill burden	3.5	2.11–5.83
Poor awareness of complications	2.62	1.47–4.67
Living far from the facility	2.53	1.35–4.74

The strongest predictor is feeling fine. A well-controlled hypertensive patient has no symptom prompting them to return, so the only thing standing between them and disengagement is the clinic's ability to notice and call. That is not a motivational problem to be solved with better counselling alone — it is an information problem about who is due and who did not arrive.

HIV care: the losses are front-loaded

Two Ethiopian retention studies show when patients disappear, which is more actionable than knowing how many.

In a rural hospital pre-ART cohort of 626 adults followed 2010–2013, 178 patients (28.4%) were lost to follow-up, and 93% of those losses occurred within the first six months 2. Median follow-up time before loss was 6.13 months, and patients not started on co-trimoxazole prophylaxis were at higher risk (AHR 1.77, 95% CI 1.12–2.79) 2.

In an Amhara ART cohort of 542 adults, the incidence density of loss to follow-up was 13.45 per 100 person-years (95% CI 11.78–15.34), with poor drug adherence the strongest predictor (AHR 3.04, 95% CI 2.18–4.24) 3.

Different diseases, different decades, same shape: disengagement is common and it happens early.

Source: Yirga et al. 2024 [1]; Shaweno & Shaweno 2015 [2]

Show data table

	Where retention fails, across three Ethiopian cohorts
Pre-ART losses occurring in the first 6 months	93%
Hypertensive patients non-adherent to follow-up	39.2%
Pre-ART patients lost to follow-up overall	28.4%

The operational reading: the highest-risk window is the beginning of care, not the long tail. A clinic that concentrates follow-up effort on the first six months after enrolment is working where the evidence says the losses are.

What this implies for how a clinic runs

1. The list that matters is "expected today and did not arrive." Most registers can produce who attended. Very few can produce who was due and is missing, which is the only list that supports tracing.
2. Front-load contact in the first six months. In pre-ART care, 93% of losses happened in that window 2.
3. Flag asymptomatic chronic patients specifically. They are the group least likely to self-motivate (AOR 4.98) 1.
4. Record a phone number that will still work. Every intervention above depends on being able to reach the patient months later.
5. Note pill burden. It nearly quadrupled the odds of missed follow-up 1 and is visible in the prescription, so it can be flagged without asking the patient anything.

What this note does not claim

None of these studies measures the financial cost of a missed appointment in an Ethiopian private clinic, and we found no Ethiopian study that does. Figures circulating on the cost of no-shows are drawn from other health systems with different payment models and do not transfer; they are not cited here.

The hypertension study is cross-sectional — it establishes association between predictors and non-adherence, not causation, and it covers four hospitals in one zone 1. The two retention studies are HIV-specific and drawn from public programmes; the pre-ART cohort dates from 2010–2013 2, so treatment guidelines have changed substantially since. Their value here is the timing pattern, which is robust across settings, rather than the absolute rates.